Supernus Pharmaceuticals buy melinda
Start price
09.08.18
/
50%
€43.88
Target price
09.08.19
€53.94
Performance (%)
-41.09%
End price
09.08.19
€25.85
Summary
This prediction ended on 09.08.19 with a price of €25.85. Massive losses of -41.09% were the result for the BUY prediction by melinda. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Supernus Pharmaceuticals | -0.763% | -0.763% | -17.197% | 3.175% |
| iShares Core DAX® | -0.654% | 1.989% | 14.984% | 18.052% |
| iShares Nasdaq 100 | 0.903% | 5.664% | 36.140% | 58.351% |
| iShares Nikkei 225® | -0.740% | -1.363% | 10.792% | 6.321% |
| iShares S&P 500 | -0.013% | 3.020% | 28.126% | 48.476% |
According to melinda what are the pros and cons of Supernus Pharmaceuticals for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Supernus Pharmaceuticals diskutieren
SecteurProduits pharmaceutiques Agenda 08/08 | 15:00 Présentation des résultat
Develops and commercializes products for the treatment of central nervous system
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases.
Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.
The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder.
The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases.
Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.
The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder.
The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
Nombre d'employés : 422 personnes.
(Laufzeit überschritten)
Stopped prediction by melinda for Supernus Pharmaceuticals
Supernus Pharmaceuticals
Start price
Target price
Perf. (%)
€25.20
25.01.21
25.01.21
€28.00
25.01.22
25.01.22
3.97%
26.01.22
26.01.22
Could be worthwhile Investment >10% per year
Supernus Pharmaceuticals
Start price
Target price
Perf. (%)
€6.88
27.01.14
27.01.14
€5.00
28.07.14
28.07.14
-1.37%
28.07.14
28.07.14
Could be worthwhile Investment >10% per year